Losmapimod + Placebo oral tablet
Phase 3Terminated 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Facioscapulohumeral Muscular Dystrophy (FSHD)
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Trial Timeline
Jun 16, 2022 → Nov 19, 2024
NCT ID
NCT05397470About Losmapimod + Placebo oral tablet
Losmapimod + Placebo oral tablet is a phase 3 stage product being developed by Fulcrum Therapeutics for Facioscapulohumeral Muscular Dystrophy (FSHD). The current trial status is terminated. This product is registered under clinical trial identifier NCT05397470. Target conditions include Facioscapulohumeral Muscular Dystrophy (FSHD).
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05397470 | Phase 3 | Terminated |
Competing Products
12 competing products in Facioscapulohumeral Muscular Dystrophy (FSHD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACE-083 + ACE-083 or placebo | Merck | Phase 2 | 52 |
| ACE-083 | Merck | Phase 2 | 52 |
| Placebo + RO7204239 | Roche | Phase 2 | 52 |
| AOC-1020 + Placebo | Avidity Biosciences | Phase 3 | 74 |
| Apitegromab + Placebo | Scholar Rock Holding | Phase 2 | 49 |
| Losmapimod oral tablet + Placebo oral tablet | Fulcrum Therapeutics | Phase 2 | 44 |
| Losmapimod | Fulcrum Therapeutics | Phase 2 | 44 |
| Losmapimod | Fulcrum Therapeutics | Phase 2 | 44 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| Placebo + ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |